CN107454904B - 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域 - Google Patents

对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域

Info

Publication number
CN107454904B
CN107454904B CN201680019907.XA CN201680019907A CN107454904B CN 107454904 B CN107454904 B CN 107454904B CN 201680019907 A CN201680019907 A CN 201680019907A CN 107454904 B CN107454904 B CN 107454904B
Authority
CN
China
Prior art keywords
ala
leu
gly
asp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680019907.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107454904A (zh
Inventor
T·巴克
M·T·斯通普
H·K·宾茨
D·菲利普斯
I·多拉多
P·福雷尔
F·W·默茨
I·松德雷格
D·斯泰纳
M·古罗迪-格奥尔吉耶娃
J·阿布拉姆萨力巴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of CN107454904A publication Critical patent/CN107454904A/zh
Application granted granted Critical
Publication of CN107454904B publication Critical patent/CN107454904B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
CN201680019907.XA 2015-04-02 2016-04-01 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域 Active CN107454904B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15162511.8 2015-04-02
EP15162511 2015-04-02
EP15162502 2015-04-02
EP15162502.7 2015-04-02
PCT/EP2016/057272 WO2016156596A1 (en) 2015-04-02 2016-04-01 Designed ankyrin repeat domains with binding specificity for serum albumin

Publications (2)

Publication Number Publication Date
CN107454904A CN107454904A (zh) 2017-12-08
CN107454904B true CN107454904B (zh) 2026-06-19

Family

ID=55650423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680019907.XA Active CN107454904B (zh) 2015-04-02 2016-04-01 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域

Country Status (20)

Country Link
US (3) US9458211B1 (enExample)
EP (2) EP3277711B9 (enExample)
JP (1) JP6552636B2 (enExample)
KR (2) KR20220109488A (enExample)
CN (1) CN107454904B (enExample)
AU (3) AU2016240220B2 (enExample)
BR (1) BR112017020986A2 (enExample)
CA (1) CA2979602C (enExample)
CL (1) CL2017002454A1 (enExample)
CO (1) CO2017009954A2 (enExample)
ES (1) ES2953482T3 (enExample)
IL (2) IL276944B (enExample)
MX (2) MX2022008302A (enExample)
MY (1) MY179505A (enExample)
NZ (1) NZ735803A (enExample)
PH (1) PH12017501792B1 (enExample)
RU (1) RU2769470C2 (enExample)
SA (1) SA517390092B1 (enExample)
SG (1) SG11201707606RA (enExample)
WO (1) WO2016156596A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
EP3514169B1 (en) * 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
MY196882A (en) 2016-09-22 2023-05-08 Molecular Partners Ag Recombinant binding proteins and their use
CN110959015B (zh) * 2017-07-12 2023-07-25 四川科伦博泰生物医药股份有限公司 双特异性重组蛋白
CA3073125A1 (en) * 2017-08-18 2019-02-21 Cambridge Enterprise Limited Modular binding proteins
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
EP3941580A1 (en) * 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
CA3139164A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
KR20220016944A (ko) * 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 개선된 안정성을 갖는 설계된 안키린 반복 도메인
JP2022535564A (ja) * 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
EP3980452A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
CN114945584A (zh) 2019-12-11 2022-08-26 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
AU2020402581A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
MX2022013945A (es) 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
AU2021271131A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Recombinant CD40 binding proteins and their use
IL298168A (en) * 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
AU2021403658A1 (en) * 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
US20240108746A1 (en) 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
KR20230169182A (ko) * 2021-04-09 2023-12-15 몰리큘라 파트너스 아게 신규한 DARPin 기반 CD70 인게이저
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
CN114957426B (zh) * 2022-06-02 2023-05-16 华南师范大学 Sp6rars及其在防治蜚蠊目昆虫中的应用
CA3262553A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
JP2026524079A (ja) 2023-06-06 2026-07-17 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｃｄ２結合タンパク質及びその使用
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
EP4724473A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd47 binding proteins and their use
EP4788689A1 (en) 2023-10-03 2026-08-12 BicycleTx Limited Bicyclic peptide ligand complexes specific for tfr1
CN122438868A (zh) 2024-01-05 2026-07-21 分子合作伙伴股份公司 多特异性结合蛋白
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2026013280A1 (en) 2024-07-11 2026-01-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Designed ankyrin repeat proteins binding p53, and uses thereof
WO2026093563A2 (en) 2024-10-31 2026-05-07 Molecular Partners Ag Multispecific binding proteins and their use
WO2026150109A1 (en) 2025-01-10 2026-07-16 Molecular Partners Ag Mesothelin-specific binding constructs and their use in radiotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
KR101268939B1 (ko) 2005-07-08 2013-05-30 유니버시티 오브 취리히 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
BR112013000452A2 (pt) * 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
CN104634971A (zh) * 2010-07-19 2015-05-20 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
MX2013005847A (es) * 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
WO2012149439A2 (en) 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Also Published As

Publication number Publication date
US9458211B1 (en) 2016-10-04
KR20220109488A (ko) 2022-08-04
US20160289285A1 (en) 2016-10-06
IL254788A0 (en) 2017-12-31
MX393655B (es) 2025-03-24
JP2018511327A (ja) 2018-04-26
RU2017134456A (ru) 2019-04-03
RU2769470C2 (ru) 2022-04-01
AU2021286418B2 (en) 2024-01-04
AU2016240220B2 (en) 2019-11-21
SG11201707606RA (en) 2017-10-30
KR102427117B1 (ko) 2022-07-29
CO2017009954A2 (es) 2018-02-20
EP4272838A3 (en) 2024-01-10
MX2017012485A (es) 2018-04-11
IL254788B (en) 2020-09-30
US10155791B2 (en) 2018-12-18
WO2016156596A1 (en) 2016-10-06
US20190263869A1 (en) 2019-08-29
RU2017134456A3 (enExample) 2019-10-08
EP3277711C0 (en) 2023-06-07
AU2016240220A1 (en) 2017-10-19
NZ735803A (en) 2021-12-24
US20160362453A1 (en) 2016-12-15
PH12017501792B1 (en) 2022-07-20
EP3277711B1 (en) 2023-06-07
MY179505A (en) 2020-11-09
KR20170131515A (ko) 2017-11-29
IL276944B (en) 2022-07-01
AU2021286418A1 (en) 2022-01-20
CN107454904A (zh) 2017-12-08
AU2020201264A1 (en) 2020-03-12
CL2017002454A1 (es) 2018-05-25
EP4272838A2 (en) 2023-11-08
EP3277711A1 (en) 2018-02-07
IL276944A (en) 2020-10-29
EP3277711B9 (en) 2023-08-16
JP6552636B2 (ja) 2019-07-31
HK1244009A1 (en) 2018-07-27
ES2953482T3 (es) 2023-11-13
US11332501B2 (en) 2022-05-17
CA2979602A1 (en) 2016-10-06
MX2022008302A (es) 2023-02-28
CA2979602C (en) 2022-12-20
SA517390092B1 (ar) 2022-03-03
BR112017020986A2 (pt) 2018-08-14
PH12017501792A1 (en) 2019-01-21

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant